IgG4‐Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30‐Year Tertiary care Experience. (May 2018)

• Record Type: Journal Article
• Authors: Roos, Eva; Hubers, Lowiek M.; Coelen, Robert J. S.; Doorenspleet, Marieke E.; de Vries, Niek; Verheij, Joanne; Beuers, Ulrich; van Gulik, Thomas M.
• Is Part Of: American journal of gastroenterology. Volume 113:Number 5(2018)
• Publication Date: 2018-05
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/s41395-018-0036-5
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : BACKGROUND: Distinguishing perihilar cholangiocarcinoma (PHC) from benign forms of sclerosing cholangitis affecting the hilar bile ducts is challenging, since histological confirmation of PHC is difficult to obtain and accurate non‐invasive diagnostic tests are not available. IgG4‐associated cholangitis (IAC), an imitator of PHC, may present with clinical and radiographical signs of PHC. IAC can be accurately diagnosed with a novel qPCR test. The aim of this study was to investigate the incidence and long‐term activity of IAC in patients resected for PHC in a single tertiary center over a period of 30 years. METHODS: All patients with benign disease who underwent surgery for presumed PHC in our institute between 1984 and 2015 were identified. Benign liver and bile duct specimens were re‐evaluated by a pathologist and scored according to international consensus pathology criteria for IgG4‐related disease (IgG4‐RD). Patients with benign disease still alive were followed‐up and a clinical diagnosis of IAC was made using a combination of the HISORt group C (response to steroids) criteria and elevated serum IgG4 levels and/or the novel IgG4/IgG RNA ratio. Also, recurrent symptomatic disease at any time after surgery requiring immunosuppression was assessed. RESULTS: Out of 323 patients who underwent surgery for presumed PHC, 50 patients (15%) had benign disease. In 42% ( n =21/50) of these patients a histological ( n = 17) or clinical ( n = 4) diagnosis of IAC was established. The remaining patients were diagnosed with unclassified sclerosing inflammation, cystadenoma, or sclerosing hemangioma. Nine out of 12 IAC patients who were followed‐up showed episodes of recurrent disease requiring immunosuppressive treatment. CONCLUSIONS: Liver and bile duct resections for PHC during three decades disclosed in 15% benign biliary disorders mimicking PHC of which 42% were definitely diagnosed as IAC. IgG4‐RD remains active in the majority of patients with IAC years after surgery. Novel diagnostic tests for IAC might reduce misdiagnosis, unnecessary surgery, and life‐threatening complications.